Clinical and Histologic Analysis of the Efficacy of Topical Rapamycin Therapy Against Hypomelanotic Macules in Tuberous Sclerosis Complex
- 1 July 2015
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 151 (7) , 722-730
Abstract
Research from JAMA Dermatology — Clinical and Histologic Analysis of the Efficacy of Topical Rapamycin Therapy Against Hypomelanotic Macules in Tuberous Sclerosis ComplexKeywords
This publication has 29 references indexed in Scilit:
- First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complexBritish Journal of Dermatology, 2013
- A Novel Topical Rapamycin Cream for the Treatment of Facial Angiofibromas in Tuberous Sclerosis ComplexJournal of Child Neurology, 2013
- Dramatic Improvement of Facial Angiofibromas in Tuberous Sclerosis With Topical Rapamycin: Optimizing a Treatment ProtocolArchives of Dermatology, 2011
- Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis – associated facial angiofibromaJournal of the European Academy of Dermatology and Venereology, 2011
- A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severityBritish Journal of Dermatology, 2011
- Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycinJournal of Dermatological Treatment, 2010
- The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosisBritish Journal of Dermatology, 2008
- Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signalingGenes & Development, 2003
- TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signallingNature Cell Biology, 2002
- Identification of the Tuberous Sclerosis Gene TSC1 on Chromosome 9q34Science, 1997